We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+15.6%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$8.4B
AUM Growth
+$1.66B
Cap. Flow
+$1.33B
Cap. Flow %
15.85%
Top 10 Hldgs %
61.33%
Holding
510
New
182
Increased
113
Reduced
52
Closed
146

Top Buys

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$79.7M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$74.4M
3
KVUE icon
Kenvue
KVUE
+$65.3M
4
ELF icon
e.l.f. Beauty
ELF
+$51.7M
5
GSK icon
GSK
GSK
+$46.6M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$96.3M
2
EXAS
Exact Sciences
EXAS
+$56.4M
3
PTCT icon
PTC Therapeutics
PTCT
+$34.5M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$28M
5
MDB icon
MongoDB
MDB
+$23M

Sector Composition

Rank Sector Weight
1 Healthcare 32.56%
2 Technology 5.44%
3 Consumer Discretionary 5.13%
4 Consumer Staples 2.69%
5 Communication Services 1.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RDDT icon
76
Reddit
RDDT
$29.9B
$17.6M 0.21%
76,600
+27,500
+56% +$5.78M
LYV icon
77
Live Nation Entertainment
LYV
$42.8B
$17.2M 0.21%
+120,938
New +$17.4M
NVO
78
Novo Nordisk
NVO
$197B
$17.1M 0.2%
336,000
-400,000
-54% -$20.5M
CROX icon
79
Crocs
CROX
$6.58B
$16.3M 0.19%
190,350
+156,870
+469% +$13.1M
KLAR
80
Klarna Group
KLAR
$7.7B
$15.9M 0.19%
+549,680
New +$18.9M
VYGR icon
81
Voyager Therapeutics
VYGR
$187M
$15.7M 0.19%
4,000,000
-200,000
-5% -$885K
TMCI icon
82
Treace Medical Concepts
TMCI
$310M
$15.6M 0.19%
6,364,000
+48,000
+0.8% +$208K
LEN icon
83
Lennar Class A
LEN
$21.2B
$15.6M 0.19%
151,295
+72,746
+93% +$8.78M
TSM icon
84
TSMC
TSM
$2.15T
$15.2M 0.18%
50,000
-6,700
-12% -$1.97M
APP icon
85
Applovin
APP
$140B
$15M 0.18%
22,262
+2,742
+14% +$1.73M
BILL icon
86
BILL Holdings
BILL
$4.81B
$14.8M 0.18%
271,389
+152,191
+128% +$7.82M
SLDB icon
87
Solid Biosciences
SLDB
$859M
$14.7M 0.18%
2,612,000
+1,676,000
+179% +$9.08M
DT icon
88
Dynatrace
DT
$14.8B
$14.6M 0.17%
336,000
-64,000
-16% -$2.98M
FDMT icon
89
4D Molecular Therapeutics
FDMT
$537M
$14.5M 0.17%
1,936,000
+840,000
+77% +$8.52M
PRTA icon
90
Prothena Corp
PRTA
$444M
$14.3M 0.17%
1,500,000
-324,000
-18% -$3.3M
KALV
91
DELISTED
KalVista Pharmaceuticals
KALV
$12.9M 0.15%
+800,000
New +$10.6M
BBOT
92
BridgeBio Oncology
BBOT
$718M
$12.5M 0.15%
1,000,000
+588,000
+143% +$7.12M
CNTA
93
DELISTED
Centessa Pharmaceuticals
CNTA
$12.5M 0.15%
500,000
+122,000
+32% +$3.09M
NPCE icon
94
Neuropace
NPCE
$467M
$12.2M 0.15%
792,000
-506,000
-39% -$6.77M
NVDA icon
95
NVIDIA
NVDA
$5.31T
$11.9M 0.14%
63,955
-12,989
-17% -$2.42M
ALGN icon
96
Align Technology
ALGN
$12.5B
$11.9M 0.14%
+76,104
New +$10.9M
NUVB icon
97
Nuvation Bio
NUVB
$2.22B
$11.3M 0.13%
1,263,737
-1,032,263
-45% -$6.39M
BSX icon
98
Boston Scientific
BSX
$69.2B
$10.9M 0.13%
114,025
+33,802
+42% +$3.31M
SMPL icon
99
Simply Good Foods
SMPL
$989M
$10.8M 0.13%
+536,000
New +$11.2M
NTLA icon
100
Intellia Therapeutics
NTLA
$1.53B
$10.4M 0.12%
1,156,000
+484,000
+72% +$6.66M
2 3
4
5 6

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return
DSC
Donald Smith & Co New York $5.56B AUM 47.13% 1-Year Est. Return
ACM
Altimeter Capital Management Boston, Massachusetts $5.7B AUM 36.74% 1-Year Est. Return
PI
PGGM Investments Zeist, Netherlands $5.7B AUM 17.05% 1-Year Est. Return

Armistice Capital's Q4 2025 Portfolio in Review

As of Q4 2025, Armistice Capital held 510 positions worth $8.4B, up 25% from $6.74B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Armistice Capital deployed $1.33B of net new capital in Q4 2025, opening 182 new positions and adding to 113 existing holdings. Its largest new stake was Kenvue: 3,992,196 shares worth $68.9M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 32% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Travere Therapeutics, an estimated $96.3M trimmed.

  • Armistice Capital's largest Q4 2025 buy was Kenvue: 3,992,196 shares worth $68.9M.
  • Armistice Capital added most to Agios Pharmaceuticals in Q4 2025, an estimated $79.7M increase.
  • Armistice Capital's biggest Q4 2025 reduction was Travere Therapeutics, cutting an estimated $96.3M.
  • Armistice Capital fully exited Exact Sciences in Q4 2025, selling an estimated $56.4M.
  • Armistice Capital's ten largest holdings make up 61% of its $8.4B portfolio in Q4 2025.
  • Armistice Capital opened 182 new positions and closed 146 in Q4 2025.
  • Armistice Capital's portfolio value rose 25% quarter-over-quarter to $8.4B.

Based on Armistice Capital's 13F filing for Q4 2025, filed 17 Feb 2026.